Coronary Plaque Regression: A Review of the Role of Lipid-Lowering Agents

Area of Science:

• Cardiology
• Pharmacology
• Medical Imaging

Background:

• Coronary artery disease (CAD) poses a significant global health burden.
• Lipid-lowering therapies (LLT) are crucial in reducing CAD morbidity and mortality.
• Advanced imaging techniques enable assessment of atherosclerotic plaque changes.

Purpose of the Study:

• To review the evidence on the effectiveness of various lipid-lowering therapies in promoting coronary artery plaque regression.
• To highlight the role of advanced imaging in evaluating plaque changes in response to treatment.

Main Methods:

• Literature review of studies investigating lipid-lowering agents and their impact on coronary plaque.
• Analysis of data from imaging modalities such as intravascular ultrasound, optical coherence tomography, and coronary CT angiography.
• Synthesis of evidence on plaque composition and volume changes associated with LLT.

Main Results:

• LLTs, particularly statins and PCSK9 inhibitors, effectively lower low-density lipoprotein cholesterol.
• Evidence suggests these therapies can lead to regression of coronary artery plaque volume and favorable changes in composition.
• Imaging surrogates indicate a reduction in atherosclerotic burden with effective lipid lowering.

Conclusions:

• Lipid-lowering therapies are effective in reducing cardiovascular mortality and morbidity associated with CAD.
• Advanced imaging modalities provide valuable insights into the plaque-stabilizing and regression effects of LLTs.
• Further research can optimize LLT strategies for maximal plaque regression and improved patient outcomes.